24×7 Emergency Care

1-8-31/1, Minister Road, Secunderabad, Telangana 500003

EMERGENCY:Stroke or TIA in a young adult (under 50) without conventional risk factors, or recurrent pregnancy loss with neurological symptoms — antiphospholipid syndrome must be excluded. —call040-46324365immediately — 24 hours, 7 days— 24/7

NEUROLOGICAL MANIFESTATIONS OF SYSTEMIC DISEASES

Antiphospholipid Syndrome — Neurological Complications Treatment in Hyderabad — KIMS Neuroscience

Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disorder in which antiphospholipid antibodies — a family of autoantibodies that bind to phospholipid-binding proteins — activate the coagulation system and promote thrombosis in both arteries and veins. The neurological manifestations of APS are predominantly thrombotic: stroke and TIA are the most common, making APS one of the leading causes of stroke in young adults in India. However, APS also causes a range of non-thrombotic neurological syndromes — cognitive impairment, chorea, headache and migraine, transverse myelitis, and Sneddon syndrome — through mechanisms that include direct antibody-mediated neuronal injury and microvascular thrombosis.

View Our Specialists

About This Condition

Antiphospholipid Syndrome at a Glance

Definition

Autoimmune thrombophilia from antiphospholipid antibodies · Arterial + venous thrombosis.

Three antibodies

Lupus anticoagulant (LA) · Anti-cardiolipin IgG/IgM (aCL) · Anti-beta2-glycoprotein I IgG/IgM (β2GPI).

Diagnosis

Positive on TWO occasions, ≥12 weeks apart (Sapporo / revised criteria).

Triple positivity

All 3 antibodies positive = highest thrombotic risk · Most important for treatment decisions.

Most common neurological

Ischaemic stroke and TIA — the most common arterial thrombosis in APS.

Other neurological

CVST · Cognitive impairment · Chorea · Transverse myelitis · Sneddon syndrome.

Sneddon syndrome

Livedo reticularis (mottled skin) + stroke — often APL positive · Characteristic clinical entity.

Primary vs secondary

Primary APS: no SLE · Secondary APS: within SLE — higher recurrence risk.

Treatment

Lifelong anticoagulation with warfarin (INR 2–3, arterial; 2–3 or 3–4 if recurrent).

India note

Young stroke workup frequently omits APL panel · Major cause of underdiagnosis and recurrent stroke.

About This Condition

Antiphospholipid Syndrome — Autoimmune Thrombophilia with Neurological Predominance

APS may be primary (occurring without an associated systemic disease) or secondary (associated with another autoimmune condition, most commonly SLE). Secondary APS within SLE carries a particularly high risk of recurrent thrombosis. The critical clinical challenge of APS in India is the underdiagnosis: the antiphospholipid antibody panel is not routinely included in the initial stroke workup for young adults in many centres, and young Indian adults with stroke are frequently managed without APS being identified or treated.

Emergency / Consultation

Speak directly with the KIMS APS and young stroke team — all coordinated under one roof for APL panel testing, anticoagulation, hydroxychloroquine initiation, and pregnancy planning.

040-44885000Emergency: 040-46324365

The Laboratory and Pathophysiological Foundations

Antiphospholipid Antibodies and Thrombosis Mechanism

Three foundational principles that shape how APS is tested for and treated at KIMS

The three antiphospholipid antibodies and their significance

The three antiphospholipid antibodies form the laboratory cornerstone of APS diagnosis: Lupus anticoagulant (LA) — named paradoxically because it prolongs coagulation tests in vitro (aPTT) but promotes thrombosis in vivo. LA is detected by the dilute Russell's viper venom time (dRVVT) test and mixing studies. LA is the strongest individual predictor of thrombotic risk. Anti-cardiolipin antibody (aCL IgG and IgM) — measured by ELISA. IgG isotype is more thrombogenic than IgM. Medium-to-high titre positivity (above 40 GPL units for IgG) is clinically significant. Anti-beta2-glycoprotein I antibody (anti-β2GPI IgG and IgM) — measured by ELISA. IgG isotype correlates more strongly with thrombosis than IgM. All three antibodies must be measured simultaneously in the initial evaluation.

Triple positivity — the highest-risk antibody profile

Triple positivity — simultaneous positivity for all three antibodies (LA + aCL IgG + anti-β2GPI IgG) — is associated with the highest risk of thrombosis, recurrent thrombosis, and pregnancy morbidity. In clinical practice, triple-positive APS patients are treated more aggressively: higher INR targets (3.0–4.0 for recurrent arterial thrombosis on standard anticoagulation), avoidance of DOACs (direct oral anticoagulants, which are inferior to warfarin in triple-positive APS per the TRAPS trial), and hydroxychloroquine as additional antithrombotic therapy (in SLE-associated APS and in primary APS).

Non-thrombotic mechanisms — direct antibody-mediated neurological injury

Not all neurological manifestations of APS are caused by thrombosis. Anti-β2GPI antibodies can directly bind to phospholipid-binding proteins on neuronal cell membranes, disrupting neuronal function and contributing to cognitive impairment. In chorea (involuntary writhing movements in APS), antibodies bind to neurons in the basal ganglia. In migraine and headache, antibodies may affect the endothelium of cerebral vessels. These non-thrombotic mechanisms explain why some APS neurological syndromes (cognitive impairment, chorea) may not respond to anticoagulation alone and may require hydroxychloroquine or other immunomodulatory treatment.

From Stroke to Chorea to Cognitive Impairment

Major Neurological Syndromes in APS

Six core neurological manifestations that shape APS clinical recognition at KIMS

Ischaemic stroke and TIA — the dominant neurological manifestation

Stroke and TIA are the most common neurological manifestation of APS and the most common arterial thrombotic event. APS accounts for approximately 13–14% of all strokes in young patients under 50, and a much higher proportion (up to 50% in some series) of cryptogenic stroke in young adults. The MRI pattern in APS stroke: multiple ischaemic infarcts in different arterial territories simultaneously (from multiple small emboli or multiple arterial occlusions) or single large-territory infarction. In a young adult with stroke and no atrial fibrillation, no carotid stenosis, and no cardiac embolism, APS is the next most important diagnosis to test for. At KIMS, APL panel is included in the young stroke protocol as standard.

Cerebral venous sinus thrombosis (CVST) — the venous thrombotic manifestation

CVST in APS presents identically to CVST from other causes: progressive headache over days to weeks, papilloedema, visual blurring, and sixth nerve palsy from raised intracranial pressure. Focal deficits or seizures occur when the venous obstruction causes venous infarction with haemorrhage. MR venography confirms the dural sinus occlusion. APL antibodies are found in approximately 20–25% of CVST patients — a much higher proportion in young women without conventional risk factors. Treatment: anticoagulation for CVST + hydroxychloroquine + consider long-term warfarin if APL antibodies are confirmed on repeat testing.

Sneddon syndrome — livedo reticularis with stroke

Sneddon syndrome is the combination of livedo reticularis (a fixed, mottled, net-like bluish-purple discolouration of the skin, particularly over the thighs, trunk, and forearms) with recurrent stroke or TIA, particularly in young women. Approximately 50–60% of Sneddon syndrome patients are APL-positive. The livedo reflects small vessel thrombosis in the skin (the same thrombophilic tendency that causes cerebral vessel thrombosis). The clinical implication: livedo reticularis in a young woman with stroke should immediately trigger APL antibody testing. Warfarin for confirmed APL-positive Sneddon syndrome.

Chorea in APS — the involuntary movement disorder

Chorea (rapid, involuntary, irregular movements of the face, limbs, and trunk) is an uncommon but well-recognised non-thrombotic manifestation of APS. It results from direct APL antibody binding to basal ganglia neurons. Chorea may be unilateral (hemi-chorea) or bilateral. It can be the presenting manifestation of APS — before any thrombotic event. In young women with sudden-onset chorea (particularly during pregnancy or with oral contraceptive use), APS must be excluded. Treatment: hydroxychloroquine (most effective for APS chorea) + haloperidol or clonazepam for symptomatic chorea control.

Cognitive impairment and white matter lesions — the chronic neurological burden

Chronic APS produces cognitive impairment through two mechanisms: recurrent micro-thrombosis causing progressive small vessel disease (white matter hyperintensities on MRI, subcortical ischaemia), and direct anti-β2GPI antibody-mediated neuronal injury. The cognitive profile is frontal-subcortical: slowed processing speed, executive dysfunction, attentional impairment, and memory difficulties. In older APS patients, this can closely resemble vascular dementia. Optimising INR control (preventing further thrombotic events) and hydroxychloroquine are the most important interventions for cognitive protection.

Transverse myelitis in APS

Spinal cord involvement in APS is uncommon but important. Transverse myelitis (rapid-onset paraplegia + sensory level + bladder/bowel dysfunction) from APS spinal cord ischaemia or inflammation produces an acute myelopathy. When AQP4 antibody is positive in a patient with APS myelitis, NMOSD coexisting with APS is the diagnosis. The treatment of APS myelitis: anticoagulation for the APS + IV methylprednisolone for the acute inflammatory component.

Diagnosis at KIMS

APS is diagnosed at KIMS through a structured four-stage workflow that begins with the defining antiphospholipid antibody panel on two occasions at least 12 weeks apart, uses MRI with DWI and MR venography to characterise the cerebral arterial and venous picture, runs the SLE evaluation to distinguish primary from secondary APS, and adds transoesophageal echocardiography for Libman-Sacks endocarditis and valvular thickening :

The antiphospholipid antibody panel — the defining investigation

All three antibodies on two occasions at least 12 weeks apart: Lupus anticoagulant (dRVVT + mixing studies) · Anti-cardiolipin IgG and IgM (ELISA) · Anti-beta2-glycoprotein I IgG and IgM (ELISA). Important: aCL and anti-β2GPI titres are reported as GPL (IgG phospholipid units) and MPL (IgM). Low-positive (<40 GPL) is of uncertain significance and does not meet Sapporo criteria. Medium-positive (40–80 GPL) and high-positive (>80 GPL) are clinically significant. The 12-week gap between tests is to exclude transient antibody positivity from infection (many acute infections transiently raise APL antibodies).

MRI brain with DWI and MR venography

DWI identifies acute ischaemic strokes — multiple infarcts in different vascular territories simultaneously is characteristic of APS. T2/FLAIR shows white matter hyperintensities from chronic small vessel disease. MRV confirms CVST by showing filling defects in dural sinuses. Gadolinium shows cortical and dural sinus enhancement in acute CVST.

SLE evaluation — to determine primary vs secondary APS

ANA · Anti-dsDNA · Complement C3, C4 · CBC (lymphopenia, thrombocytopenia) · Urinalysis and renal function (lupus nephritis) · Skin examination and history (photosensitivity, malar rash, discoid lesions). Secondary APS (within SLE) requires treatment of both APS (anticoagulation) and SLE (hydroxychloroquine, immunosuppression).

Echocardiography — for Libman-Sacks and valvular thickening

Libman-Sacks endocarditis (sterile mitral valve vegetations) occurs in both SLE and primary APS. TOE is more sensitive than TTE. Valvular thickening and regurgitation are associated with APS and can be a source of cardiac embolism contributing to stroke. If Libman-Sacks is found and APL antibodies are positive, anticoagulation is the primary treatment.

Treatment

Treatment at KIMS

Five Integrated Treatment Pillars

Warfarin, DOAC Avoidance, Hydroxychloroquine, Aspirin, and Catastrophic APS Triple Therapy

Anticoagulation — The Cornerstone of APS Neurological Treatment: Lifelong anticoagulation with warfarin (vitamin K antagonist) is the standard treatment for APS with arterial thrombosis (stroke/TIA). Target INR: First arterial event, single or double APL positivity: INR 2.0–3.0. Recurrent arterial event on therapeutic INR, or triple-positive APS: INR 3.0–4.0 (higher target). Venous thrombosis (CVST) only: INR 2.0–3.0. Duration: minimum 6 months for provoked; lifelong for unprovoked or recurrent CVST with confirmed APS.

DOACs — Why They Are Avoided in Triple-Positive APS: DOACs (rivaroxaban, dabigatran, apixaban) are NOT recommended for triple-positive APS with arterial thrombosis. The TRAPS trial demonstrated that rivaroxaban was inferior to warfarin in triple-positive APS with a high rate of recurrent thrombotic events.

Hydroxychloroquine — Additional Antithrombotic and Immunomodulatory: Hydroxychloroquine 200–400 mg/day has antithrombotic properties (platelet inhibition, anti-inflammatory) and reduces APL antibody titres over time. It is recommended in all SLE-associated APS patients and is increasingly used in primary APS, particularly for non-thrombotic manifestations (chorea, cognitive impairment, headache) and as additional antithrombotic protection.

Aspirin — Additional Antiplatelet: Low-dose aspirin (75–100 mg/day) is added to warfarin in arterial APS with recurrent events despite therapeutic INR. In asymptomatic APL-positive individuals (no prior thrombosis), aspirin alone is used for primary prevention, particularly if there is triple positivity or additional cardiovascular risk factors.

Catastrophic APS — Triple Therapy: Catastrophic APS (CAPS) is a rare, life-threatening form of APS with simultaneous multiorgan thrombosis within a short period. Treatment: heparin + IV methylprednisolone + IVIg or plasma exchange. Rituximab and eculizumab are used for refractory CAPS. Call 040-46324365 for any patient with multiorgan failure and suspected APS.

Related Conditions

Antiphospholipid syndrome neurological complications belong to the family of neurological manifestations of systemic diseases evaluated and managed at KIMS Neuroscience. Explore related conditions or return to the hub.

FAQs

Frequently Asked Questions

Yes — if your lupus anticoagulant is confirmed positive on a second test 12 weeks after the first (and ideally all three APL antibodies are measured), and the stroke was attributed to APS rather than another mechanism, lifelong warfarin anticoagulation is the standard treatment. Aspirin alone is insufficient for secondary prevention of arterial thrombosis in confirmed APS — the risk of recurrent stroke on aspirin alone is approximately 20–29% per year, compared to 3–5% per year on warfarin. The 12-week repeat test is important because a single positive lupus anticoagulant during an acute thrombotic event can be transiently positive from the thrombosis itself, and diagnosis requires persistence. At KIMS, warfarin is started with INR monitoring every 2–4 weeks until stable, then every 8–12 weeks. Call 040-44885000.

For triple-positive APS (all three antibodies positive) with arterial thrombosis (stroke), rivaroxaban and other direct oral anticoagulants (DOACs) are not recommended. The TRAPS clinical trial specifically tested rivaroxaban versus warfarin in APS patients and found that rivaroxaban had a significantly higher rate of recurrent thrombosis — including recurrent stroke. This has led to a clear clinical recommendation: warfarin is preferred over DOACs in triple-positive APS with arterial events. For patients with variable INR control, strategies include more frequent INR monitoring, dietary counselling (consistent vitamin K intake from leafy vegetables), and patient education on medication interactions. At KIMS, the anticoagulation clinic provides structured INR monitoring and education. If your APL profile is single-positive (LA or aCL only) and you had venous thrombosis (not arterial), the DOAC question is less clear-cut and can be discussed with your haematologist. Call 040-44885000.

Yes — chorea (involuntary writhing movements) is a recognised non-thrombotic neurological manifestation of APS. It results from antiphospholipid antibodies directly binding to neurons in the basal ganglia (the brain region that controls involuntary movement), disrupting their function. It is not caused by a blood clot (so anticoagulation alone may not resolve it) and responds best to hydroxychloroquine, which reduces antibody titres and modulates the immune response in the basal ganglia. Symptomatic control of the movements uses haloperidol, clonazepam, or tetrabenazine while hydroxychloroquine takes effect (typically 6–8 weeks). Corticosteroids are rarely needed for APS chorea. MRI brain is performed to confirm the absence of a basal ganglia ischaemic lesion. Call 040-44885000.

Pregnancy in APS is a high-risk situation requiring specialised obstetric and haematological management at KIMS. Warfarin is teratogenic in the first trimester (causes fetal warfarin syndrome) and must be switched to low-molecular-weight heparin (LMWH — such as enoxaparin) at the time of confirmed pregnancy. LMWH does not cross the placenta and is safe for the fetus. Aspirin 75–100 mg/day is added throughout pregnancy. Warfarin is resumed postpartum (safe in breastfeeding). The risks to monitor: recurrent miscarriage (APS is the leading treatable cause of recurrent pregnancy loss), pre-eclampsia, placental insufficiency, and maternal thrombosis. At KIMS, high-risk obstetrics, haematology, and neurology collaborate for the management of pregnant women with APS. Call 040-44885000 before or as soon as pregnancy is confirmed.

Young adult stroke in India without an explanation. Recurrent miscarriage in a young woman. Livedo reticularis with TIA. Chorea in a woman under 40. These are the presentations of antiphospholipid syndrome — a condition that is missed because the blood test (lupus anticoagulant + anti-cardiolipin + anti-beta2-GPI) is not included in the standard stroke workup.

At KIMS Hyderabad, the young stroke protocol includes the full APL panel as standard. Call 040-44885000. Emergency: 040-46324365.

040-44885000

International enquiries: info@kimsneurosciences.com